Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations.
Selim
Magdy
M
Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. mselim@bidmc.harvard.edu
D000818:Animals; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003676:Deferoxamine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006454:Hemoglobins / Q000009:adverse effects; D006801:Humans; D009410:Nerve Degeneration / Q000209:etiology / Q000517:prevention & control; D017262:Siderophores / Q000627:therapeutic use*
D006454:Hemoglobins; D017262:Siderophores; D003676:Deferoxamine